Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Sponsor: Brazilian Clinical Research Institute
Summary
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.
Official title: A 2 x 2 Factorial Randomized Clinical Trial Evaluating Anti-inflammatory and Anti-thrombotic Strategy in Acute Ischemic Stroke
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
4500
Start Date
2026-07
Completion Date
2027-12
Last Updated
2026-02-11
Healthy Volunteers
No
Conditions
Interventions
Rivaroxaban 2.5 Mg Oral Tablet
Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
Colchicine 0.5 MG
Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
Placebo Rivaroxaban
Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
Placebo Colchicine
Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.